PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

Trial Profile

PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Rucaparib (Primary) ; Rucaparib (Primary) ; Cisplatin
  • Indications Breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
    • 12 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 20 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top